<DOC>
	<DOCNO>NCT00975091</DOCNO>
	<brief_summary>The purpose study determine treatment entecavir safe well tolerated patient complete dose previous entecavir study China , require treatment chronic hepatitis B virus infection .</brief_summary>
	<brief_title>Continue Entecavir Rollover From China</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Subjects complete required dosing period previous ETV Phase 2 3 study China ( study AI463012 , AI463023 , AI463056 ) , assess Investigators likely benefit additional therapy treatment HBV infection ALT â‰¤ 15 x upper limit normal Compensated liver disease Coinfection HIV , HCV , HDV</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>